Wu Shuiqing, Xu Ran, Wan Qi, Zhu Xuan, Zhang Lei, Jiang Hongyi, Zhao Xiaokun
Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Neural Medical Center of the First Hospital in Changsha City, Changsha, China.
PLoS One. 2015 Apr 24;10(4):e0125087. doi: 10.1371/journal.pone.0125087. eCollection 2015.
To assess the value of anaplastic lymphoma kinase for the diagnosis of inflammatory myofibroblastic tumours using a comprehensive meta-analysis.
We searched the related literature using electronic databases and manual searches. Approximately 454 cases from several countries were included in this analysis. The quality of studies included was assessed by QUADAS (quality assessment of studies of diagnostic accuracy). The diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), sensitivity and specificity were calculated to assess the role of anaplastic lymphoma kinase in the diagnosis of inflammatory myofibroblastic tumours. The overall test performance was summarised by an SROC (summary receiver operating characteristic curve). The heterogeneity and publication bias were analysed using Meta-regression and Deeks' test. All data were analysed by Stata 12.0 software.
Eight studies were included according to our inclusion criteria. The overall results for the specificity, sensitivity, PLR, NLR, DOR and area under the curve (AUC) were 0.99 (95% CI 0.82-1.00), 0.67 (95% CI 0.46-0.83), 0.67 (95% CI 0.46-0.83), 60.6 (95% CI 3.3-1112.4), 0.33 (95% CI 0.19-0.60), 181 (95% CI 9-3684) and 0.95 (95% CI 0.93-0.97), respectively, while the specificity, sensitivity, PLR, NLR, DOR and AUC for bladder IMTs were 0.99 (95% CI 0.67-1.00), 0.86 (95% CI 0.58-0.96), 95.6 (95% CI 2.0-4616.2), 0.14 (95% CI 0.04-0.50), 671 (95% CI 16-28913) and 0.99 (95% CI 0.97-0.99), respectively.
The present meta-analysis indicated that anaplastic lymphoma kinase plays a significant role in the differential diagnosis of inflammatory myofibroblastic tumours, particularly for inflammatory myofibroblastic tumours of the urinary bladder.
通过全面的荟萃分析评估间变性淋巴瘤激酶在炎性肌纤维母细胞瘤诊断中的价值。
我们使用电子数据库和手工检索来搜索相关文献。本分析纳入了来自几个国家的约454例病例。纳入研究的质量通过QUADAS(诊断准确性研究的质量评估)进行评估。计算诊断比值比(DOR)、阳性似然比(PLR)、阴性似然比(NLR)、敏感性和特异性,以评估间变性淋巴瘤激酶在炎性肌纤维母细胞瘤诊断中的作用。通过汇总受试者工作特征曲线(SROC)总结总体检验性能。使用Meta回归和Deeks检验分析异质性和发表偏倚。所有数据均使用Stata 12.0软件进行分析。
根据我们的纳入标准,纳入了八项研究。特异性、敏感性、PLR、NLR、DOR和曲线下面积(AUC)的总体结果分别为0.99(95%可信区间0.82 - 1.00)、0.67(95%可信区间0.46 - 0.83)、0.67(95%可信区间0.46 - 0.83)、60.6(95%可信区间3.3 - 1112.4)、0.33(95%可信区间0.19 - 0.60)、181(95%可信区间9 - 3684)和0.95(95%可信区间0.93 - 0.97),而膀胱炎性肌纤维母细胞瘤的特异性、敏感性、PLR、NLR、DOR和AUC分别为0.99(95%可信区间0.67 - 1.00)、0.86(95%可信区间0.58 - 0.96)、95.6(95%可信区间2.0 - 4616.2)、0.14(95%可信区间0.04 - 0.50)、671(95%可信区间16 - 28913)和0.99(95%可信区间0.97 - 0.99)。
本荟萃分析表明,间变性淋巴瘤激酶在炎性肌纤维母细胞瘤的鉴别诊断中起重要作用,特别是对于膀胱炎性肌纤维母细胞瘤。